Free Trial
→ Elon Musk about to bankrupt Amazon, Microsoft & Google? (From Brownstone Research) (Ad)tc pixel
NASDAQ:RXRX

Recursion Pharmaceuticals Q3 2026 & Study Update Earnings Date & Estimates

Recursion Pharmaceuticals logo
$4.03 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$4.10 +0.06 (+1.61%)
As of 07:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Recursion Pharmaceuticals is estimated to report Q3 2026 & Study Update earnings on Monday, November 2, 2026, before market opens. The conference call is scheduled for November 3, 2026 at 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026 & Study Update
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Recursion Pharmaceuticals in Q3 2026 & Study Update

Recursion Pharmaceuticals is expected to post earnings of -$0.2190 per share on revenue of $14.81 million. In the same quarter a year earlier Recursion Pharmaceuticals reported -$0.36 per share on revenue of $5.18 million. Recursion Pharmaceuticals last reported on August 5, 2026, posting -$0.25 per share and missing the -$0.24 consensus estimate. Recursion Pharmaceuticals has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.2190
Expected Revenue
$14.81 million
Prior-Year EPS
-$0.36
Prior-Year Revenue
$5.18 million
Expected Revenue Growth
+186.1%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.25 (Missed by -$0.01)
Last Quarter Revenue
$7.67 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 & Study Update Call

Recursion Pharmaceuticals Q3 2026 & Study Update Earnings FAQ

Recursion Pharmaceuticals (NASDAQ:RXRX) is estimated to report Q3 2026 & Study Update earnings on Monday, November 2, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Recursion Pharmaceuticals' Q3 2026 & Study Update earnings conference call is scheduled for Tuesday, November 3, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Recursion Pharmaceuticals to post earnings of -$0.2190 per share for Q3 2026 & Study Update.

The consensus revenue estimate for Recursion Pharmaceuticals is $14.81 million for Q3 2026 & Study Update.

Recursion Pharmaceuticals Earnings Headlines

Recursion Pharmaceuticals (RXRX) Stock May Be Fully Priced As REC 4881 Data Nears
 |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/recursion-pharmaceuticals-rxrx-stock-may-042843082.html
Recursion Pharmaceuticals (RXRX) Projected to Announce Quarterly Earnings on Monday
November 1 at 3:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31171555
Elon says the ‘S’ word
Elon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men described the same moment in strikingly similar terms: a technological tipping point they call the Singularity. James Altucher says the idea once belonged to science fiction. Now he connects it to a move Musk could make as soon as January 27, and lays out what both men see coming in a short presentation.tc pixel
November 2 at 1:00 AM  |  Paradigm Press (Ad)
1 Big Winner and 1 Loser From the Upcoming Anthropic IPO
October 31 at 6:45 PM  |  fool.comhttps://www.fool.com/investing/2026/10/31/1-big-winner-and-1-loser-from-the-anthropic-ipo/
Earnings To Watch: Recursion Pharmaceuticals Inc (RXRX) Q3 2026 -- GF Value Sees 35% Downside
October 30 at 7:49 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/earnings-watch-recursion-pharmaceuticals-inc-132635268.html
Recursion Pharmaceuticals (RXRX) vs. Its Competitors Critical Contrast
October 30 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31167096
See More Recursion Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Recursion Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Recursion Pharmaceuticals and other key companies, straight to your email.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals (NASDAQ:RXRX) is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases. The company develops selected drug candidates internally and also works with pharmaceutical and biotechnology partners to use its technology for target discovery, compound design and preclinical research. Its pipeline has included programs based on both new and existing therapeutic approaches.

Founded in 2013 and headquartered in Salt Lake City, Utah, Recursion operates as a technology-enabled drug discovery company serving global pharmaceutical and biotechnology markets. In 2024, it completed a combination with Exscientia plc, another company focused on artificial intelligence-driven drug design, expanding its capabilities in computational chemistry and automated discovery. Recursion was co-founded and is led by Chief Executive Officer Christopher D. Gibson.

View Recursion Pharmaceuticals Profile
Earnings Tools